# EDGAR Filing Document

**Accession Number:** 0001665074
**File Stem:** 0001094891-26-000179
**Filing Date:** 2026-4
**Character Count:** 28229
**Document Hash:** ba21ee34642b64de12f2ce3902558d6a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001094891-26-000179.hdr.sgml**: 20260409

**ACCESSION NUMBER**: 0001094891-26-000179

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260409

**DATE AS OF CHANGE**: 20260409

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PAVmed Inc.
- **CENTRAL INDEX KEY:** 0001624326
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 471214177
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-89489
- **FILM NUMBER:** 26852939

**BUSINESS ADDRESS:**
- **STREET 1:** 360 MADISON AVENUE
- **STREET 2:** 25TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017
- **BUSINESS PHONE:** (212) 949-4319

**MAIL ADDRESS:**
- **STREET 1:** 360 MADISON AVENUE
- **STREET 2:** 25TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PAXmed Inc.
- **DATE OF NAME CHANGE:** 20141105
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Aklog Lishan
- **CENTRAL INDEX KEY:** 0001665074

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**MAIL ADDRESS:**
- **STREET 1:** 420 LEXINGTON AVENUE
- **STREET 2:** SUITE 300
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10171

## Ex-99

Form of Restricted Stock Agreement 
```
<pre>
                      RESTRICTED STOCK AGREEMENT

THIS RESTRICTED STOCK AWARD AGREEMENT (this "Agreement") is made as of the
Grant Date by and between PAVmed Inc., a Delaware corporation (the
"Company"), and Grantee.

WHEREAS, pursuant to the terms and conditions of the Company's 2014 Long-
Term Incentive Equity Plan, as amended (the "Plan"), the Compensation
Committee (the "Committee") of the Board of Directors of the Company (the
"Board") has authorized the grant to the Grantee of an award of Restricted
Stock (as defined in the Plan) in the amount of the number of shares of the
authorized but unissued common stock of the Company, $.001 par value
("Common Stock") set forth in the table below opposite "Number of Shares
Subject to Award" (the "Restricted Shares"), conditioned upon the Grantee's
acceptance thereof upon the terms and conditions set forth in this
Agreement and subject to the terms of the Plan (capitalized terms used
herein and not otherwise defined have the meanings set forth in the
Plan); and

WHEREAS, the Grantee desires to acquire the Restricted Shares on the
terms and conditions set forth in this Agreement and subject to the terms
of the Plan;

Grantee:
Grant Date:
Number of Shares Subject to Award:
Vesting Schedule: See Vest Schedule online on etrade.com

IT IS AGREED:

1.	Grant of Restricted Shares. The Company hereby grants to the Grantee
an award of the Restricted Shares on the terms and conditions set forth
herein and subject to the provisions of the Plan.

2.	Consideration. The grant of the award of Restricted Stock is made
in consideration of the services to be rendered by the Grantee to the
Company.

3.	Effect of Change of Control; Other Termination.

      3.1.	Change of Control. If a Change of Control (as defined by
Section 9 of the Plan, Accelerated Vesting and Exercisability, including
the transactions described in sections 9.1 and 9.2 of the Plan) occurs at
or prior to a termination of Grantee's employment, then all of the
Restricted Shares shall immediately vest upon such Change of Control.

      3.2.	Other Termination. If Grantee's employment is terminated
for any reason prior to the vesting in full of the Restricted Shares,
Grantee shall retain any vested Restricted Shares, and any unvested
Restricted Shares shall not vest and shall be forfeited upon such termination
in accordance with Section 4, and neither the Company nor any Affiliate
shall have any further obligations to the Grantee under this Agreement with
respect to such unvested Restricted Shares. In the event of a termination
of Grantee's employment simultaneously with a Change of Control, Section
3.1 shall govern.

      3.3.	Service Agreement.  In the event of any conflict between
the terms of Grantee's employment agreement or other service agreement
with the Company by which Grantee is bound (the "Service Agreement") and
this Section 3, with respect to the vesting of the Restricted Shares upon
a Change of Control or the termination of Grantee's employment, the terms
of the Service Agreement shall govern.

4.	Vesting; Forfeiture.  Any Restricted Shares and Retained Distributions
(as defined below) with respect thereto that upon termination of Grantee's
employment are unvested (after application of the terms of Section 3 or the
Grantee's Service Agreement, as applicable) shall be forfeited to the Company
and Grantee shall not thereafter have any rights with respect to such
Restricted Shares and Retained Distributions that shall have been so
forfeited.

5.	Restrictions. Subject to any exceptions set forth in this Agreement
or the Plan, none of the unvested Restricted Shares nor the rights relating
thereto (including any Retained Distributions with respect to such unvested
Restricted Shares) may be assigned, alienated, pledged, attached, sold, or
otherwise transferred or encumbered by the Grantee. Any attempt to assign,
alienate, pledge, attach, sell, or otherwise transfer or encumber any
unvested Restricted Shares or the rights relating thereto shall be wholly
ineffective.

6.	Rights and Obligations as Stockholder.  The Restricted Shares shall
constitute issued and outstanding shares of Common Stock for all corporate
purposes. Grantee will have the right to vote such Restricted Shares and
to exercise all other rights, powers and privileges of a holder of Common
Stock with respect to such Restricted Shares, with the exceptions that
(i) Grantee will not be entitled to delivery of the stock certificate or
certificates representing any Restricted Shares until the applicable
Restriction Period shall have expired; (ii) the Company will retain custody
of the stock certificate or certificates representing the Restricted Shares
during the applicable Restriction Period; (iii) the Company will retain
custody of all dividends and distributions ("Retained Distributions") made,
paid or declared with respect to the Restricted Shares (and such Retained
Distributions will be subject to the same restrictions, terms and conditions
as are applicable to the Restricted Shares) until such time, if ever, as
the Restricted Shares with respect to which such Retained Distributions shall
have been made, paid or declared shall have become vested; and (iv) a breach
of any of the restrictions, terms or conditions contained in the Plan or
this Agreement or otherwise established by the Committee with respect to any
Restricted Shares or Retained Distributions will cause a forfeiture of such
Restricted Shares and any Retained Distributions with respect thereto.

7.	Certificates. The Restricted Shares, when issued, will be represented
by a stock certificate or certificates registered in the name of Grantee.
Certificates representing any unvested Restricted Shares and any securities
constituting Retained Distributions shall bear a legend to the effect that
ownership of the unvested Restricted Shares (and such Retained Distributions)
and the enjoyment of all rights appurtenant thereto are subject to the
restrictions, terms and conditions provided in the Plan and this Agreement.
Such certificates shall be deposited by Grantee with the Company, together
with stock powers or other instruments of assignment, each endorsed in
blank, which will permit the transfer to the Company of all or any portion
of the unvested Restricted Shares and any securities constituting Retained
Distributions that shall be forfeited or that shall not become vested in
accordance with the Plan and this Agreement.

8.	Tax Matters.

      8.1.	Not later than the date as of which an amount first becomes
includible in the gross income of the Grantee for Federal income tax purposes
with respect to the Restricted Shares, the Grantee shall pay to the Company,
or make arrangements satisfactory to the Committee regarding the payment of,
any Federal, state and local taxes of any kind required by law to be withheld
or paid with respect to such amount ("Withholding Tax"). The obligations of
the Company under the Plan and pursuant to this Agreement shall be
conditional upon such payment or arrangements with the Company and the
Company shall, to the extent permitted by law, have the right to deduct any
Withholding Taxes from any payment of any kind otherwise due to the
Grantee from the Company.

      8.2.	Any required Withholding Tax may be paid:

            8.2.1.	in cash by wire transfer, certified or bank check or
personal check, in each case payable to the order of the Company; or

            8.2.2.	provided that prior approval of the Committee has been
obtained, in shares of Common Stock of the Company owned by Grantee,
including vested Restricted Shares, by delivery of stock certificates in
negotiable form or with stock powers or other instruments of assignment, each
endorsed in blank, which are effective to transfer good and valid title
thereto to the Company, free of any liens or encumbrances. Shares of Common
Stock used for this purpose shall be valued at the Fair Market Value.

      8.3.	Notwithstanding the foregoing, the Company shall have the right
to reject payment in the form of Common Stock if in the opinion of counsel
for the Company, (i) it could result in an event of "recapture" under Section
16(b) of the Securities Exchange Act of 1934; (ii) such shares of Common
Stock may not be sold or transferred to the Company; or (iii) such transfer
could create legal difficulties for the Company.

      8.4.	Notwithstanding any action the Company takes with respect to
any or all income tax, social insurance, payroll tax, or other tax-related
withholding ("Tax-Related Items"), the ultimate liability for all Tax-
Related Items is and remains the Grantee's responsibility and the Company
(a) makes no representation or undertakings regarding the treatment of any
Tax-Related Items in connection with the grant or vesting of the Restricted
Shares or the subsequent sale of any Restricted Shares; and (b) does not
commit to structure the Restricted Shares to reduce or eliminate the
Grantee's liability for Tax-Related Items.

      8.5.	The Grantee may make an election under Section 83(b) of the Code
(a "Section 83(b) Election") with respect to the Restricted Shares. Any such
election must be made within thirty (30) days after the Grant Date. If the
Grantee elects to make a Section 83(b) Election, the Grantee shall provide
the Company with a copy of an executed version and satisfactory evidence of
the filing of the executed Section 83(b) Election with the U.S. Internal
Revenue Service. The Grantee agrees to assume full responsibility for
ensuring that the Section 83(b) Election is actually and timely filed with
the US Internal Revenue Service and for all tax consequences resulting
from the Section 83(b) Election.

9.	Company Representations. The Company hereby represents and warrants
to the Grantee that:

      9.1.	the Company, by appropriate and all required action, is duly
authorized to enter into this Agreement and consummate all of the
transactions contemplated hereunder; and

      9.2.	the Restricted Shares, when issued and delivered by the Company
to the Grantee in accordance with the terms and conditions hereof, will be
duly and validly issued and fully paid and non-assessable.

10.	Grantee Representations. The Grantee hereby represents and warrants
to the Company that:

      10.1.	they are acquiring the Restricted Shares for their own account
and not with a view towards the distribution thereof;

      10.2.	they have received a copy of the Plan as in effect as of the
date of this Agreement;

      10.3.	they have received a copy of all reports and documents required
to be filed by the Company with the Securities and Exchange Commission
pursuant to the Exchange Act, within the last 24 months and all reports
issued by the Company to its stockholders;

      10.4.	they understand that they are subject to the Company's Insider
Trading Policy and have received a copy of such policy as of the date of
this Agreement;

      10.5.	they understand that they must bear the economic risk of the
investment in the Restricted Shares, which cannot be sold by them unless
they are registered under the Securities Act of 1933 ("1933 Act") or an
exemption therefrom is available thereunder and that the Company is under
no obligation to register the Restricted Shares for sale under the 1933 Act;

      10.6.	in their position with the Company, they have had both the
opportunity to ask questions and receive answers from the officers and
directors of the Company and all persons acting on its behalf concerning the
terms and conditions of the offer made hereunder and to obtain any
additional information to the extent the Company possesses or may possess
such information or can acquire it without unreasonable effort or expense
necessary to verify the accuracy of the information obtained pursuant to
Section 10.3 above;

      10.7.	they are aware that the Company shall place stop transfer
orders with its transfer agent against the transfer of the Restricted Shares
in the absence of registration under the 1933 Act or an exemption therefrom
as provided herein, and for so long as the Restricted Shares are unvested;
and

      10.8.	they are aware that, for so long as the Restricted Shares remain
unvested, the certificates evidencing the Restricted Shares shall bear the
following legend:

                "THE SHARES REPRESENTED BY THIS CERTIFICATE
                HAVE BEEN ACQUIRED PURSUANT TO A RESTRICTED
                STOCK AGREEMENT DATED, A COPY OF WHICH IS ON
                FILE WITH THE COMPANY, AND MAY NOT BE
                TRANSFERRED, PLEDGED OR DISPOSED OF EXCEPT IN
                ACCORDANCE WITH THE TERMS AND CONDITIONS
                THEREOF."

11.	Restriction on Transfer of Restricted Shares. Anything in this Agreement
to the contrary notwithstanding, the Grantee hereby agrees that they shall
not sell, transfer by any means or otherwise dispose of the Restricted
Shares acquired by Grantee unless (i) the Restricted Shares are registered
under the 1933 Act, or in the event that they are not so registered, an
exemption from the 1933 Act registration requirements is available thereunder
and the Grantee has furnished the Company with notice of such proposed
transfer and the Company's legal counsel, in its reasonable opinion, shall
deem such proposed transfer to be so exempt, and (ii) such transfer is in
compliance with the Company's Insider Trading Policy, as in effect at such
time.

12.	Adjustments. If any change is made to the outstanding Common Stock
or the capital structure of the Company, if required, the shares of Common
Stock shall be adjusted or terminated in any manner as contemplated by
Section 3.2 of the Plan.

13.	Miscellaneous.

      13.1.	Notices. All notices, requests, deliveries, payments, demands
and other communications which are required or permitted to be given under
this Agreement shall be in writing and shall be either delivered personally
or sent by registered or certified mail, or by private courier to the parties
at their respective addresses set forth herein, or to such other address
as either party shall have specified by notice in writing to the other.
Notice shall be deemed duly given hereunder when delivered or mailed as
provided herein.

      13.2.	Conflicts with the Plan. This Agreement is subject to the Plan
as approved by the Company's stockholders. The terms and provisions of the
Plan as it may be amended from time to time are hereby incorporated herein
by reference. In the event of a conflict between the provisions of the Plan
and the provisions of this Agreement, the provisions of this Agreement
shall in all respects be controlling.

      13.3.	Grantee Rights. Nothing contained in this Agreement shall be
deemed to confer upon Grantee any right to continued employment with Company
or any affiliate thereof, nor shall it interfere in any way with the right
of the Company to terminate Grantee in accordance with the provisions
regarding such termination set forth in the Service Agreement.

      13.4.	Amendment. The Committee has the right to amend, alter,
suspend, discontinue or cancel the Restricted Shares, prospectively or
retroactively; provided, that, no such amendment shall adversely affect
the Grantee's material rights under this Agreement without the
Grantee's consent.

      13.5.	Waiver. The waiver by any party hereto of a breach of any
provision of this Agreement shall not operate or be construed as a waiver
of any other or subsequent breach.

      13.6.	Entire Agreement. This Agreement, together with the Plan,
constitutes the entire agreement between the parties with respect to the
subject matter hereof. This Agreement may not be amended except by writing
executed by the Grantee and the Company.

      13.7.	Binding Effect; Successors. The Company may assign any of its
rights under this Agreement. This Agreement shall inure to the benefit of
and be binding upon the parties hereto and, to the extent not prohibited
herein, their respective heirs, successors, assigns and representatives.
Nothing in this Agreement, expressed or implied, is intended to confer on any
person other than the parties hereto and as provided above, their respective
heirs, successors, assigns and representatives any rights, remedies,
obligations or liabilities.

      13.8.	Governing Law. This Agreement shall be governed by and construed
in accordance with the laws of the State of Delaware (without regard to
choice of law provisions).

      13.9.	Severability. The invalidity or unenforceability of any provision
of the Plan or this Agreement shall not affect the validity or enforceability
of any other provision of the Plan or this Agreement, and each provision
of the Plan and this Agreement shall be severable and enforceable to the
extent permitted by law.

      13.10.	Discretionary Nature of Plan. The Plan is discretionary
and may be amended, cancelled or terminated by the Company at any time,
in its discretion. The grant of the Restricted Shares in this Agreement
does not create any contractual right or other right to receive any
Restricted Shares or other awards in the future. Future awards, if any,
will be at the sole discretion of the Company. Any amendment, modification,
or termination of the Plan shall not constitute a change or impairment of
the terms and conditions of the Grantee's employment with the Company
or any of its affiliates.

      13.11.	Headings. The headings contained herein are for the
sole purpose of convenience of reference, and shall not in any way limit
or affect the meaning or interpretation of any of the terms or provisions
of this Agreement.

      13.12.	No Impact on Other Benefits. The value of the Grantee's
Restricted Shares is not part of his or her normal or expected compensation
for purposes of calculating any severance, retirement, welfare, insurance
or similar employee benefit.

      13.13.	Counterparts. This Agreement may be executed in counterparts,
each of which shall be deemed an original but all of which together will
constitute one and the same instrument. Counterpart signature pages to this
Agreement transmitted by facsimile transmission, by electronic mail in
portable document format (.pdf), or by any other electronic means, will have
the same effect as physical delivery of the paper document bearing an original
signature.

      13.14.	Acceptance. The Grantee hereby acknowledges receipt of a
copy of the Plan and this Agreement. The Grantee has read and understands the
terms and provisions thereof, and accepts the Restricted Shares subject to
all of the terms and conditions of the Plan and this Agreement. The Grantee
acknowledges that there may be adverse tax consequences upon the grant or
vesting of the Restricted Shares or disposition of the underlying shares and
that the Grantee has been advised to consult a tax advisor prior to such
grant, vesting or disposition.

                           Signature Page Follows]

IN WITNESS WHEREOF, the parties hereto have signed this Agreement
as of the day and year first above:

PAVMED INC.

By:
Name: Lishan Aklog, M.D.
Title: Chairman and CEO
Date:

GRANTEE:

                  [Signature Page to Restricted Stock Agreement]

        </pre>
```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**PAVmed Inc.**

*(Name of Issuer)*

**Common Stock, par value $0.001 per share**

*(Title of Class of Securities)*

**—**

*(CUSIP Number)*

**Lishan Aklog**<br>360 MADISON AVENUE<br>25TH FLOOR<br>NEW YORK NY 10017<br>(917) 813-1828

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**04/02/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Aklog Lishan** | Name of reporting person<br>**Aklog Lishan** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**369023.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**45.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**369023.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**45.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**369068.00** | Aggregate amount beneficially owned by each reporting person<br>**369068.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**5.1%** | Percent of class represented by amount in Row (11)<br>**5.1%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.001 per share

**(b) Name of Issuer:**
PAVmed Inc.

**(c) Address of Issuer's Principal Executive Offices:**
360 MADISON AVENUE, 25TH FLOOR, NEW YORK, NY, 10017

This Schedule 13D is filed by Lishan Aklog, M.D. ("Dr. Aklog" or the "Reporting Person") with respect to ownership of the common stock, par value $0.001 per share ("Common Stock"), of PAVmed Inc., a Delaware corporation (the "Issuer"). The percentage of beneficial ownership reflected in this Schedule 13D is based upon 7,272,739 shares of Common Stock outstanding as of April 2, 2026.

**Item 4. Purpose of Transaction**

Dr. Aklog acquired beneficial ownership of the shares of Common Stock described in this Schedule 13D for investment purposes. Dr. Aklog may from time to time acquire beneficial ownership of additional securities for investment purposes, or dispose of securities, in the open market or in private transactions, including upon exercise of options described below and subject to the restricted stock agreements described below. At the date of this Schedule 13D, except as set forth in this Schedule 13D, and as consistent with Dr. Aklog's position as Chairman and Chief Executive Officer of the Issuer, Dr. Aklog has no plans or proposals which would result in:

(a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer;

(b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries;

(c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries;

(d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of the board of directors or management of the Issuer;

(e) Any material change in the present capitalization or dividend policy of the Issuer;

(f) Any other material change in the Issuer's business or corporate structure;

(g) Changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person;

(h) Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association;

(i) A class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act; or

(j) Any action similar to any of those actions enumerated above.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Dr. Aklog beneficially owns 369,068 shares of Common Stock, comprised of (i) 357,614 shares of Common Stock held by Dr. Aklog, (ii) 45 shares of Common Stock held by HCFP/AG LLC, which Dr. Aklog may be deemed to beneficially own because he serves as a co-manager of such entity, (iii) 9,904 shares of Common Stock held by Pavilion Venture Partners LLC, which Dr. Aklog may be deemed to beneficially own because he serves as manager of such entity, (iv) 10 shares of Common Stock held by Dr. Aklog's children, and (v) 1,495 shares of Common Stock issuable upon the exercise of the options held by Dr. Aklog.

**(b)**
Dr. Aklog has sole power to vote and dispose of 369,023 shares, comprised of the shares held by Dr. Aklog, the shares held by Pavilion Venture Partners LLC, the shares held by Dr. Aklog's children, and the shares subject to options held by Dr. Aklog.

Dr. Aklog has shared power to vote and dispose of 45 shares, comprised of the shares held by HCFP/AG LLC.

**(c)**
On April 2, 2026, the Issuer granted Dr. Aklog 350,000 shares of restricted Common Stock, pursuant to the Issuer's Seventh Amended and Restated Long-Term Incentive Equity Plan.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Dr. Aklog is party to option agreements and restricted stock agreements with the Issuer. The option agreements provide for Dr. Aklog to purchase 618, 433, and 444 shares of Common Stock, respectively, at exercise prices of $2,250.00, $904.50, and $715.50, respectively, and expire on April 28, 2026, February 14, 2028 and February 18, 2032, respectively. The restricted stock agreements cover 555, 333, 5,000 and 350,000 shares of restricted stock, respectively, granted to Dr. Aklog on May 1, 2020, April 1, 2021, September 30, 2025 and April 2, 2026, respectively, with single vesting dates of May 20, 2026, May 20, 2026, May 20, 2028 and May 20, 2029, respectively.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Aklog Lishan

**Signature:** /s/ Lishan Aklog, M.D.

**Name/Title:** Lishan Aklog, M.D.

**Date:** 04/09/2026